Myriad Genetics
OverviewSuggest Edit
Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
| Type | Public | |
| Founded | 1991 | |
| HQ | Salt Lake City, UT, US | Map |
| Website | myriad.com | |
| Employee Ratings | More | |
| Overall Culture | B- | More |
Recent NewsAll News
- Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
- Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan
- SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
- Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Key People/Management at Myriad Genetics
Bryan Riggsbee
Interim President and CEO, Chief Financial Officer
Paul J. Diaz
President and CEO
Patrick Burke
Executive Vice President, Emerging Products
Raymond Francot
Executive Vice President, International Operations
Bryan Dechairo
Officer, Executive Vice President, Development
Clivetty Martinez
Chief Compliance Officer
Myriad Genetics Office Locations
Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations
Salt Lake City, UT, US (HQ)
320 Wakara Way
Austin, TX, US
3300 Duval Rd
South San Francisco, CA, US
180 Kimball Way
South San Francisco, CA, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
41 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Myriad Genetics Financials and Metrics
Myriad Genetics Revenue
Myriad Genetics's revenue was reported to be $638.60 m in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 638.6m |
Net income (FY, 2020) | (199.6m) |
EBIT (FY, 2020) | (231.7m) |
Market capitalization (8-Feb-2021) | 2.3b |
Closing stock price (8-Feb-2021) | 30.4 |
Cash (30-Jun-2020) | 163.7m |
EV | 2.4b |
Myriad Genetics's current market capitalization is $2.3 b.
Annual
Quarterly
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 87.9m | 88.7m | 97.4m | 93.3m | 90.6m | 84.9m | 89.9m | 81.2m | |
Accounts Receivable | 113.2m | 121.1m | 123.7m | 119.1m | 116.6m | 142.6m | 4.8m | 118.3m | 102.5m |
Prepaid Expenses | 9.5m | 9.8m | 10.1m | 11.5m | 12.5m | 11.3m | 14.0m | 16.2m | |
Inventories | 38.9m | 38.2m | 33.4m | 35.9m | 33.3m | 31.9m | 28.1m | 28.1m | 30.8m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 81.1m | 113.2m | 124.6m | (700.0k) | 1.9m | 8.8m | (20.6m) | (28.9m) | (144.1m) |
Depreciation and Amortization | 13.2m | 26.3m | 39.3m | 18.3m | 36.3m | 54.6m | 18.2m | 36.4m | 54.3m |
Inventories | 3.3m | 4.1m | 8.9m | 3.5m | 6.1m | 7.4m | 3.1m | 2.6m | |
Accounts Payable | 400.0k | 3.0m | (2.0m) | (8.4m) | (300.0k) | (8.1m) | (9.3m) | (11.3m) | (2.1m) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 321.4k |
Debt/Equity | 0.3 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.6 x |
Myriad Genetics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Myriad Women’s Health | May 29, 2018 | $408.60 m |
| Myriad Neuroscience | August 03, 2016 | $351.60 m |
| Sividon Diagnostics | May 31, 2016 | $56 m |
| Privatklinik Dr. Robert Schindlbeck | February 27, 2015 | $20.10 m |
| Crescendo Bioscience | February 04, 2014 | $270 m |
| Rules-Based Medicine | April 27, 2011 | $80 m |
| Javelin Pharmaceuticals | December 18, 2009 | $95 m |
| NaturNorth Technologies | April 10, 2008 | |
| AssureRx Canada, Ltd | ||
| Assurex Health, Inc. |
Myriad Genetics Revenue Breakdown
Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing
Myriad Genetics Cybersecurity Score
Myriad Genetics Environment, Social & Governance (ESG) Ratings
Myriad Genetics Online and Social Media Presence
6.2k Twitter followers
Myriad Genetics has 6.2k Twitter Followers. The number of followers has increased 0.3% month over month and increased 1.4% quarter over quarter
Myriad Genetics's Trends
Twitter Engagement Stats for @myriadgenetics
17.2k
Tweets
858
Following
6.2k
Followers
16
Tweets last 30 days
1.1
Avg. likes per Tweet
81.3%
Tweets with engagement
Myriad Genetics Company Culture
Overall Culture
B-
70/100
CEO Rating
D
61/100
Compensation
B
74/100
Myriad Genetics News and Updates
February 02, 2021
Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched the new Vectra® Cardiovascular Risk assessment that can predict the risk for cardiovascul…
January 19, 2021
Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan
Patients with Prostate or Pancreatic Cancer to Benefit from Treatment with Lynparza
January 18, 2021
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Myriad Genetics, Inc. (NASDAQ: MYGN). If you...
January 11, 2021
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct link or through the investor section of Myriad’s website at www.myriad.com.
January 08, 2021
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice® Diagnostic System, which helps determine if women with ovarian canc…
January 05, 2021
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available…
Myriad Genetics Blogs
February 25, 2021
Celebrating Diversity at Myriad Genetics
Here at Myriad Genetics, we take every opportunity to rejoice in our team’s diversity. During Black History Month, we’ve been doing
The post Celebrating Diversity at Myriad Genetics appeared first on Myriad Genetics, Inc..
February 05, 2021
February Is National Cancer Prevention Month
In honor of National Cancer Prevention Month, we wanted to raise awareness of some actions you can take right now to
The post February Is National Cancer Prevention Month appeared first on Myriad Genetics, Inc..
January 29, 2021
New Publication Demonstrates Value of Combining Clinical and Genetic Risk Models for More Accurate Breast Cancer Risk Prediction
By Thomas Slavin, M.D., Senior Vice President of Medical Affairs, Oncology A new, peer-reviewed paper published in JCO Precision Oncology shows
The post New Publication Demonstrates Value of Combining Clinical and Genetic Risk Models for More Accurate Breast Cancer Risk Prediction appeared first on…
January 19, 2021
How Genetic Testing Saved My Life
It was 6 years ago that I learned I was BRCA2+. The Myriad myRisk® test was encouraged by my OB/GYN based
The post How Genetic Testing Saved My Life appeared first on Myriad Genetics, Inc..
December 10, 2020
Myriad Genetics Recognizes Three Distinguished Directors for 55 Years of Combined Board Service
At the December meeting of its Board of Directors, Myriad Genetics recognized the meaningful contributions of three retiring board members —
The post Myriad Genetics Recognizes Three Distinguished Directors for 55 Years of Combined Board Service appeared first on Myriad Genetics, Inc..
November 12, 2020
From Genetic Counselor to President: A Personal Chat with Nicole Lambert, President, Myriad Genetic Laboratories, Sharing the Passion for Improving Lives
Today, on Genetic Counselors Awareness Day, we at Myriad Genetics want to recognize and show appreciation to all the genetic counselors who dedicate themselves
The post From Genetic Counselor to President: A Personal Chat with Nicole Lambert, President, Myriad Genetic Laboratories, Sharing the Pass…
Myriad Genetics Frequently Asked Questions
When was Myriad Genetics founded?
Myriad Genetics was founded in 1991.
Who are Myriad Genetics key executives?
Myriad Genetics's key executives are Bryan Riggsbee, Paul J. Diaz and Patrick Burke.
How many employees does Myriad Genetics have?
Myriad Genetics has 2,600 employees.
What is Myriad Genetics revenue?
Latest Myriad Genetics annual revenue is $638.6 m.
What is Myriad Genetics revenue per employee?
Latest Myriad Genetics revenue per employee is $245.6 k.
Who are Myriad Genetics competitors?
Competitors of Myriad Genetics include Progenity, Foundation Medicine and Genomic Health.
Where is Myriad Genetics headquarters?
Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.
Where are Myriad Genetics offices?
Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations.
How many offices does Myriad Genetics have?
Myriad Genetics has 13 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies